Tekmira Pharmaceuticals this week announced that it has signed a deal giving ag-bio firm Monsanto the option to license its proprietary lipid-based RNAi delivery technology for use in agricultural applications.

Over the four-year term of the option, Tekmira will provide Monsanto with lipid formulations in exchange for undisclosed payments to maintain the option. If Monsanto choses to exercise its option, it will pay an undisclosed fee to Tekmira and receive an exclusive, worldwide license to its delivery technology in agriculture.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

Mary Beckerle has been removed as director of the Huntsman Cancer Institute in what one researcher refers to as a "coup," ScienceInsider reports.

Bill Gates tells the Telegraph that bioterrorism is a serious risk.

The March for Science is to take place tomorrow, and supporters are tapping their creative energies to create placards to carry.

CBS News reports that the White House Science Fair is to continue under President Donald Trump.